Healthcare company Baxter International (NYSE:BAX) in Q2 CY2025, with sales up 4.3% year on year to $2.81 billion. On the other hand, next quarter’s revenue guidance of $2.87 billion was less ...

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the first quarter of 2024. “Baxter’s results in the first quarter reflect ...

Healthcare company Baxter International (NYSE:BAX) reported Q4 CY2025 results topping the market’s revenue expectations, with sales up 8% year on year to $2.97 billion. Its non-GAAP profit of $0.44 ...

Q4 results: Sales were $3.0 billion (up 8% reported, 3% operational) but adjusted EPS was $0.44, missing expectations due to margin pressure—adjusted gross margin fell to 35.5% (down ~900 bps)—and a ...

Baxter International (BAX) reported $2.97 billion in revenue for the quarter ended December 2025, representing a year-over-year increase of 8%. EPS of $0.44 for the same period compares to $0.58 a ...

As Baxter International Inc (NYSE:BAX) prepares to release its second-quarter 2023 financial results on July 27, Stifel analyst writes it is an opportune time for investors to consider owning BAX ...

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the second quarter of 2023. “Baxter’s second-quarter performance reflects ...

Baxter has been a poor performer over the last year. The stock now trades with an extremely low valuation relative to the stock's historical performance. Recently, the company raised guidance, which ...

Q4 sales performance exceeded guidance, driven by better-than-expected sales in Medical Products, Kidney Care, Pharmaceuticals. Baxter reported improved profitability in fourth quarter. Brand New ...

Provides updates on Baxter’s 2030 Corporate Responsibility Commitment and Goals and reinforces the company’s commitment to transparent reporting “Baxter employees across the globe are connected by our ...